Anteo Diagnostics Ltd (ASX:ADO) will launch five new medical test products at a three day U.S. based conference, currently in progress.

Anteo uses its patented nanotechnology to develop and commercialise products for sale into the life sciences, in-vitro diagnostics (IVD), point of care, medical devices and energy markets.

The U.S. conference is a premier industry event where breakthrough innovations in clinical testing and patient care are introduced to the healthcare community.

The new products will target the life sciences and IVD markets.

The product launch follows a strong June quarter highlighting strong growth from the recently acquired DIAsource Immunoassays SA and progress regarding the company";s ambitions to apply its nanotechnology to battery markets.

Jef Vangenechten, CEO, commented: 'We believe that these products are a new milestone for Anteo";s technology as they prove that the chemistry can be applied across the diversity of surface materials used in the IVD POC industry.

'This will allow Anteo to continue building a product portfolio that better addresses unmet customer needs.”


Product launch details

Anteo will unveil five new products at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo to be held August 2-4 in Philadelphia.

Details of the products being launched are as follows:

- Lateral flow coupling test kit;
- Antibody coupling test kit;
- Magnetic separation coupling test kit;
- Zika virus ELISA assay; and
- Expansion of the Free-25OH Vitamin D assay into the IVD market.

The World Health Organization has declared the Zika virus an international public health emergency, prompted by growing concern that it could cause birth defects.

As many as four million people could be infected by the end of the year.

The interest in measuring 25OH Vitamin D keeps growing worldwide reaching a total market value of US$1.2 billion in 2016


June quarter highlights

Anteo";s recently acquired DIAsource business recorded its 4th consecutive quarter of revenue growth, recording €4.07 million and growing 11% on the corresponding quarter.

A sales agreement was signed with the Egyptian Government for US$1.77 million to deliver a variety of clinical tests for the first 12 month period starting in the second half of 2016.

Finally, during May the Anteo Energy business undertook Asia meetings with the world";s largest manufacturing and component suppliers of lithium-ion batteries.

Anteo";s unique nano-chemistry enables improvement in both anode and cathode performance in lithium-ion batteries allowing them to store more energy and last longer.


Analysis

The launch of these five new products are further evidence of Anteo";s ability to present new products that have targeted applications in commercially viable markets.

These products show that the chemistry in Anteo";s technology can be applied across a diverse range of surface testing materials.

The continued double digit sales growth from DIAsource underpins a stable platform for Anteo to grow its business and reputation in the scientific community.

Meetings with the large battery companies have confirmed the interest and opportunities that the company";s technology can offer within the growing lithium-ion battery market.

Anteo had $3.76 million in cash at the end of the June quarter and the company decreased its operating expenditure during the quarter by 55%.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.